High-dose
Consolidation therapy
High-dose 131I-mIBG therapy
Relapsed neuroblastoma
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
08
07
2020
accepted:
13
08
2020
pubmed:
31
8
2020
medline:
24
8
2021
entrez:
31
8
2020
Statut:
ppublish
Résumé
Children with relapsed neuroblastoma have a poor prognosis despite modern multimodality therapy. Novel and more effective therapeutic strategies are required for relapsed neuroblastoma. We retrospectively examined the utility of consolidation therapy with high-dose Between December 2009 and 2014, five patients with relapsed neuroblastoma and one with relapsed ganglioneuroblastoma received high-dose During follow-up, three children showed no signs of disease relapse, whereas three died. One child without a relapse died from post-transplant side effects, and two children with a relapse died owing to tumor progression. The 5-year progression-free and overall survival rates after Consolidation therapy with high-dose
Identifiants
pubmed: 32862362
doi: 10.1007/s12149-020-01514-2
pii: 10.1007/s12149-020-01514-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM